Recon: Pfizer to conclude $43B Seagen purchase after giving away cancer drug rights; J&J touts phase 3 results for multiple myeloma therapy

• New sickle cell disease CRISPR treatments can’t make up for the shortage of adult hematologists (STAT)
• A Final LDT Rule in April!? Will FDA be Prepared? (FDA Law Blog)
• Puberty Blocker Petition Raises Questions About When FDA Should Weigh In On Off-Label Drug Use (Pink Sheet)
• Rx Drug Ads Should Not Characterize Probability Of Risk As Insignificant, FDA Emphasizes (Pink Sheet)
• US diabetes patients face delays as insurers tighten Ozempic coverage (Reuters)
• Weight loss from Lilly's Zepbound reversed after stopping treatment, study shows (Reuters)
• White House wants to set minimum cyber standards for hospitals, healthcare (MedTech Dive)

• EU publishes its first list of more than 300 critical medicines, vaccines (Reuters)
• EU Explains Steps Sponsors Must Take When Using Companion Diagnostics In Drug Development (Pink Sheet)
• EMA Verdict Due On Vertex/CRISPR’s Gene Editing Therapy & Reata’s Omaveloxolone (Pink Sheet)
• Gavi Provides Funding For ‘Pandemic-Ready’ Vaccine Partners (Pink Sheet)

• Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights (Reuters)
• AstraZeneca Buys into RSV Vaccine Market with Potential $1.1B Icosavax Purchas (BioSpace) (Reuters)
• Late-stage trial supports broader use of Darzalex, blockbuster J&J multiple myeloma drug (STAT)
• With big ambition — and a family name to match — Reed Jobs charts his own course in biotech (STAT)
• Tome Biosciences goes public today in another biotech megaround (STAT)
• A targeted therapy shows it can offer a ‘last, great chance’ for some acute leukemia patients (STAT)
• Moderna's chief commercial officer out as company reorganizes (Endpoints)
• Resilience plans to expand Ohio facility with 440 new jobs over three years (Endpoints)
• Almirall partners with etherna; Daiichi's RNA deal with Depixus; SQZ founder's startup emerges from stealth (Endpoints)
• After groundbreaking year for RSV approvals, GSK looks to model pediatric success for adult vaccines (Endpoints)
• Klick Health offers $1M prize pool for agency employees with innovative AI solutions (Endpoints)

• Why heart device makers are investing in left atrial appendage closure (MedTech Dive)
• Activist investor takes stake in Nevro amid struggles to grow neuromodulation sales (MedTech Dive)
• Bayer Extends Personalized Health Offering With At-Home Biological Age Test (MedTech Dive)
• Medtronic expands AI endoscopy partnership with Cosmo (MedTech Dive)
• Hologic promotes Essex Mitchell to COO (MedTech Dive)
• Class I Recall For Getinge CARDIOHELP System (MedTech Insight)
• News We’re Watching: Activist Investor Causes Kerfuffle At Nevro, Lifespin Launches Antibiotic Dx, And More (MedTech Insight)

• Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns (STAT)
• J&J, Lupin Agree Erleada Copy Won’t Infringe Cancer Drug Patent (Bloomberg)
• Teva Petitions Federal Judge in Colorado to Reject Motion to dismiss Epi-Pen Lawsuit  (FDAnews)
• Eagle Pharmaceuticals Allegedly Misled on Cancer Drug Revenue (Bloomberg)
• US consumer group seeks stronger warnings on Botox, similar treatments (Reuters)
• US panel recommends children with obesity start counseling from age 6 (Reuters)
• Sickle Cell Gene Therapy Uptake May Lag, But Still Shock State Medicaid Budgets (Pink Sheet)